Login / Signup

The Detection of Immunity against WT1 and SMAD4 P130L of EpCAM + Cancer Cells in Malignant Pleural Effusion.

Terutsugu KoyaYo NiidaMisa TogiKenichi YoshidaTakuya SakamotoHiroki UraSumihito TogiTomohisa KatoSohsuke YamadaHaruo SugiyamaShigeo KoidoShigetaka Shimodaira
Published in: International journal of molecular sciences (2022)
Malignant pleural effusion (MPE) provides a liquid tumor microenvironment model that includes cancer cells and immune cells. However, the characteristics of tumor antigen-specific CD8 + T cells have not been investigated in detail. Here, we analyzed MPE samples taken from a patient with pancreatic cancer who received a dendritic cell vaccine targeting Wilms' Tumor 1 (WT1) antigen over the disease course (two points at MPE 1st and 2 nd , two months after MPE1 st ). Epithelial cell adhesion molecule (EpCAM) + cancer cells (PD-L1 - or T cell immunoglobulin mucin-3, TIM-3 - ), both PD-1 or TIM-3 positive CD8 + T cells, and CD14 + CD68 + CD163 + TIM-3 + macrophages increased from the MPE 1st to MPE 2nd . The ratio of WT1-specific cytotoxic lymphocytes (WT1-CTLs) to MPE CD8 + T cells and IFN-γ secretion of WT1-CTLs were reduced with disease progression. Coincidentally, the fraction of central memory T (T CM ) of WT1-CTLs was decreased. On the other hand, CD8 + T cells in response to SMAD4 P130L , which is homogeneously expressed in EpCAM + cancer cells, were detected using in vitro expansion with the HLA-A*11:01 restrictive SVCVNLYH neoantigen. Furthermore, the CD8 + T cell response to SMAD4 P130L was diminished following remarkably decreased numbers of CD8 + T CM in MPE samples. In conclusion, CD8 + T cells responding to WT1 or SMAD4 P130L neoantigen expressed in EpCAM + pancreatic cancer cells were detected in MPE. A tumor antigen-specific immune response would provide novel insight into the MPE microenvironment.
Keyphrases